Clinical Trial

Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

Study acronym: LUTHREE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2018-03-05; most recent amendment 2024-09-16.
Status change: Recruiting → Active, Not Recruiting 2024-09-16
Trial Details
NCT Number NCT03454763
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions Neuroendocrine Tumors
Enrollment 618 participants
Start Date 2016-05-26
Primary Completion 2025-01 (estimated)
Study Completion 2025-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19